RxDoctor Payments Data

Joanne Lane, MD

Internal Medicine · Bryn Mawr, PANPI 1578779245

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AbbVie at 55.4% of the total. 2025 is the largest year on record at $157, more than ten times the $15 reported in 2020. That places this record below the midpoint for internal medicine clinicians in PA, where the typical reported total is $148.

$195in general payments, 2019–2025

Across 7 payments — averaging $27.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$108
  • Abbott$48
  • Pharmacyclics LLC, An Abbvie Company$24
  • EPI Health, LLC$15

What the payments were for

  • Food & beverage$195100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$195 in reported general payments places this provider in the 50th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$976,128
Medicare patients
1,127
Services billed
8,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban765$231,063
XareltoRivaroxaban182$62,311
EntrestoSacubitril/Valsartan75$26,935
MyrbetriqMirabegron90$25,060
JardianceEmpagliflozin44$17,544
Atorvastatin Calcium1,426$15,827
GemtesaVibegron50$12,696
FarxigaDapagliflozin Propanediol43$11,764
TradjentaLinagliptin41$10,553
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$10,488
Metoprolol Succinate626$10,037
NamzaricMemantine Hcl/Donepezil Hcl20$9,803
Pantoprazole Sodium793$9,711
LumiganBimatoprost32$8,647
Potassium Chloride323$8,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Lumigan$108$18,45052 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bryn Mawr

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →